Teniposide: overview of its therapeutic potential in adult cancers.
Teniposide was introduced into clinical trials prior to etoposide, but its role was not defined because interest shifted early on to etoposide. However, long-term encouraging results obtained in acute leukemia treated with teniposide have rekindled interest in this compound. In addition to pharmacokinetic differences, teniposide has greater CNS penetrance and is more lipophilic. Its greater potency is related to enhanced intracellular uptake. Although its antitumor spectrum of activity appears to be very similar to that of etoposide, a search for some differences might prove instructive.
Muggia
F M
FM
University of Southern California, Norris Cancer Center, Los Angeles 90033.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000328:Adult; D001932:Brain Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D005047:Etoposide / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008175:Lung Neoplasms / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D012514:Sarcoma, Kaposi / Q000188:drug therapy / Q000209:etiology; D013713:Teniposide / Q000627:therapeutic use* / Q000633:toxicity*
D005047:Etoposide; D013713:Teniposide